Search

Your search keyword '"Drexhage, H A"' showing total 513 results
Start Over Author "Drexhage, H A"
513 results on '"Drexhage, H A"'

3. Auto-immuniteit

Author

Kallenberg, C. G. M., Drexhage, H. A., Rijkers, G.T., editor, Kroese, F.G.M., editor, Kallenberg, C.G.M., editor, and Derksen, R.H.W.M., editor

Published
2016
Full Text
View/download PDF

14. Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial

Author

Sommer, I.E., Gangadin, S.S., Witte, L.D. de, Koops, S., Baal, C. van, Bahn, S., Drexhage, H., Haren, N.E.M. van, Veling, W., Bruggeman, R., Martens, P., Wiersma, S., Veerman, S.R.T., Grootens, K.P., Beveren, N. van, Kahn, R.S., Begemann, M.J.H., Sommer, I.E., Gangadin, S.S., Witte, L.D. de, Koops, S., Baal, C. van, Bahn, S., Drexhage, H., Haren, N.E.M. van, Veling, W., Bruggeman, R., Martens, P., Wiersma, S., Veerman, S.R.T., Grootens, K.P., Beveren, N. van, Kahn, R.S., and Begemann, M.J.H.

Abstract

Contains fulltext : 244699.pdf (Publisher’s version ) (Open Access), Schizophrenia-spectrum disorders (SSD) are associated with increased inflammatory markers, both in brain and periphery. Augmentation with drugs that lower this pro-inflammatory status may improve clinical presentation. Simvastatin crosses the blood-brain barrier, has anti- inflammatory and neuroprotective effects and reduces metabolic syndrome. In this study, we investigated if 12 months of simvastatin augmentation can improve symptoms and cognition in patients with early SSD. This double-blind placebo-controlled trial included 127 SSD patients across the Netherlands, <3 years after their diagnosis. From these, 119 were randomly assigned 1:1 to simvastatin 40 mg (n = 61) or placebo (n = 58), stratified for sex and study site. Primary outcomes were symptom severity and cognition after 12 months of treatment. Depression, symptom subscores, general functioning, metabolic syndrome, movement disorders, and safety were secondary outcomes. Intention to treat analyses were performed using linear mixed models and ANCOVA. No main effect of simvastatin treatment was found on total symptom severity after 12 months of treatment as compared to placebo (X2(1) = 0.01, P = .90). Group differences varied over time (treatment*time X2(4) = 11.2; P = .025), with significantly lower symptom severity in the simvastatin group after 6 months (mean difference = -4.8; P = .021; 95% CI: -8.8 to -0.7) and at 24 months follow-up (mean difference = -4.7; P = .040; 95% CI: -9.3 to -0.2). No main treatment effect was found for cognition (F(1,0.1) = 0.37, P = .55) or secondary outcomes. SAEs occurred more frequently with placebo (19%) than with simvastatin (6.6%). This negative finding corroborates other large scale studies on aspirin, minocycline, and celecoxib that could not replicate positive findings of smaller studies, and suggests that anti-inflammatory augmentation does not improve the clinical presentation of SSD.

Published
2021

25. Costimulation and Autoimmune Diabetes in BB Rats

Author

Beaudette-Zlatanova, B. C., Whalen, B., Zipris, D., Yagita, H., Rozing, J., Groen, H., Benjamin, C. D., Hunig, T., Drexhage, H. A., Ansari, M. J., Leif, J., Mordes, J. P., Greiner, D. L., Sayegh, M. H., and Rossini, A. A.

Published
2006

37. Het ontregelde brein; consequenties van ruimtelijke en temporele complexiteit van het brein voor pathofysiologie en diagnostiek van de bipolaire stoornis

Author

Haarman, B C M, Burger, H, Drexhage, H A, Nolen, W A, Riemersma-Van der Lek, R F, Interdisciplinair Centrum voor Psychopathologie en Emotieregulatie, Life Course Epidemiology, and Clinical Cognitive Neuropsychiatry Research Program (CCNP)

Subjects
Brain/physiopathology, Psychopathology, Bipolar Disorder/diagnosis, Humans, Biomarkers
Abstract

BACKGROUND: Despite the existence of several pathophysiological theories about bipolar disorder, it has so far been difficult to find diagnostic biomarkers and to develop new pharmacologic treatments based on the more novel theories. AIM: To reflect on the causes and consequences of problems that beset pathophysiological research into psychiatric disorders in general and bipolar disorder in particular. METHOD: In this essay we address the problems facing professionals engaged in research into bipolar disorder and we interpret these problem in the light of brain complexity. RESULTS: The complexity of the brain can be divided into two types: spatial complexity, which reflects the various physiological levels of the central nervous system (genetic, molecular, cellular, neuronal circuits and phenomenological levels), and temporal complexity, i.e. neurodevelopment. We discuss the consequences of these two types of complexity and make suggestions relating to clinical practice and pathophysiological psychiatric research. CONCLUSION: To achieve further progress in the field of brain research, we need to acquire a deeper understanding of the spatial and temporal complexity of the brain and consider the possible consequences of such knowledge for the pathophysiology and treatment of psychiatric illnesses such as bipolar disorder.

Published
2018

50. Volume, metabolites and neuroinflammation of the hippocampus in bipolar disorder

Author

Haarman, B. C. M., Riemersma-Van der Lek, R. F., Burger, H., Doorduin, J., Drexhage, H. A., Nolen, W. A., Interdisciplinary Centre Psychopathology and Emotion regulation (ICPE), Life Course Epidemiology (LCE), Molecular Neuroscience and Ageing Research (MOLAR), ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), and Clinical Cognitive Neuropsychiatry Research Program (CCNP)

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results